@Article{096504020X15929100013698,
AUTHOR = {Kazuo Umezawa, Andrzej Breborowicz, Shamil Gantsev},
TITLE = {Anticancer Activity of Novel NF-kB Inhibitor DHMEQ  by Intraperitoneal Administration},
JOURNAL = {Oncology Research},
VOLUME = {28},
YEAR = {2020},
NUMBER = {5},
PAGES = {541--550},
URL = {http://www.techscience.com/or/v28n5/48513},
ISSN = {1555-3906},
ABSTRACT = {There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic 
diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF- B inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 
2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism. 
It was shown to be a specific inhibitor that directly binds to and inactivates NF- B components. Until now, 
DHMEQ has been used by many scientists in the world to suppress animal models of cancer and inflammation. 
Especially, it was shown to suppress difficult cancer models, such as hormone-insensitive breast cancer and 
prostate cancer, cholangiocarcinoma, and multiple myeloma. No toxicity has been reported so far. DHMEQ 
was administered via the intraperitoneal (IP) route in most of the animal experiments because of its simplicity. 
In the course of developmental studies, it was found that IP administration never increased the blood concentration of DHMEQ because of the instability of DHMEQ in the blood. It is suggested that inflammatory cells in 
the peritoneal cavity would be important for cancer progression, and that IP administration, itself, is important 
for the effectiveness and safety of DHMEQ. In the present review, we describe mechanism of action, its in vivo 
anticancer activity, and future clinical use of DHMEQ IP therapy.},
DOI = {10.3727/096504020X15929100013698}
}